An EU-OPENSCREEN screening site will take the robust, miniaturised assay together with established orthogonal and counter screens through the high throughput screening (HTS) process, followed by confirmatory (dose response) and counter screening (identical assay without the target or with non-functional target), until a final list of confirmed hit compounds is established.

This process includes the following services:

  • HTS (of the entire EU-OPENSCREEN chemical collection)
  • In silico profiling, including basic chemoinformatic analysis and identification of frequent hitters and other potential false positives
  • Hit selection
  • Confirmatory screening, including orthogonal assay and IC/EC50 determination
  • Basic counter screening
  • Basic SAR based on screening data
  • QC of confirmed hits for a biochemical screen, the hit confirmation process includes testing for activity in a cell-based model.
  • Fragment based library screening
  • Virtual screening

For more information you can watch our introductory video on high-throughput-screening (HTS) here.


EU-OPENSCREEN screening partner sites:

Czech Republic (CZ):

Germany (DE):

Denmark (DK):

  • Biotech Research and Innovation Centre (BRIC), Prof. Krister Wennerberg, Dr. Cornelia Steinhauer
    Site information poster

Spain (ES):

Finland (FI):

Norway (NO):

Poland (PL):

  • Institute of Medical Biology, Polish Academy of Sciences (IMB PAS), Screening laboratory for anti-viral and anti-bacterial compounds, Prof. Dr. Zbigniew J. Leśnikowski,
    Site information poster
  • Institute of Bioorganic Chemistry (IBCH), Polish Academy of Science, Dr. Radosław Pilarski, Dr. Jacek Kolanowski,
    Detailed partner site information PDF